Foster City, Calif.-based Gilead Sciences’s Sovaldi received approval in December from the U.S. Food and Drug Administration.
The typical 12-week drug regimen costs $84,000, but some patients require the drug for a longer period of time, and guidelines suggest taking the drug along with others, adding to the overall care costs, according to a Kaiser Health News report.
J. Mario Molina, president and CEO of Molina Healthcare, a Medicaid managed care company, said in the report Medicaid programs like his will be hard hit by the financial burden of the drug.
“[Sovaldi is] far superior to anything we’ve had to treat hepatitis C. The problem is it’s extraordinarily expensive,” Mr. Molina said in the report.
Sovaldi has a success rate of more than 90 percent, and Gilead says its effectiveness warrants the high price, according to the report.
More Articles on Pharmaceuticals:
Pharmaceutical Companies Spending Less on Promotional Drug Speakers
FDA Approves Myalept to Treat Lipodystrophy Complications
Safety of Indian-Produced Drugs Being Questioned
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
